Loading clinical trials...
Loading clinical trials...
Boceprevir/Peginterferon Alfa (PegIFN α)-2b/Ribavirin (Riba) in Difficult-to-Treat Menopausal Women With Chronic Hepatitis C Genotype 1 (Gt 1), Either Deemed Nonresponders to Peginterferon/Ribavirin or Treatment-naives (MEN_BOC)
Conditions
Interventions
Pegylated Interferon, Ribavirin, Boceprevir
Locations
1
Italy
Gastroenterology Unit
Modena, Modena, Italy
Start Date
November 1, 2011
Primary Completion Date
December 1, 2013
Completion Date
June 1, 2014
Last Updated
October 2, 2012
NCT07472881
NCT05188027
NCT06691178
NCT06826755
NCT07022925
NCT06813261
Lead Sponsor
University of Modena and Reggio Emilia
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions